Sign In
Buy CDTX
$221.38
+0 (+0%)
At Close: Apr 07, 2026
MILWAUKEE , Nov. 14, 2025 /PRNewswire/ -- The Ademi Firm is investigating Cidara (Nasdaq: CDTX) for possible breaches of fiduciary duty and other violations of law in its recently announced transactio
NVDA Price Target Hikes, STUB Shows No Guidance, MRK Buying CDTX
10:00am, Friday, 14'th Nov 2025
Nvidia (NVDA) got bullish momentum from Wells Fargo and Morgan Stanley ahead of next week's earnings. Diane King Hall talks about what analysts expect from Nvidia's long-term prospects.
Merck to acquire Cidara Therapeutics for $9.2B
09:33am, Friday, 14'th Nov 2025
Merck & Co Inc (NYSE:MRK, ETR:6MK) announced it has agreed to acquire Cidara Therapeutics Inc (NASDAQ:CDTX) in a $9.2 billion cash deal, paying $221.50 per share, more than double Cidara's stock pric
CDTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Cidara Therapeutics, Inc. is Fair to Shareholders
08:06am, Friday, 14'th Nov 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Cidara Therapeutics, Inc. (NASDAQ: CDTX) to Merck for $221.50 per share in cash is fair t
Merck to Buy Cidara Therapeutics in $9.2 Billion Deal
07:16am, Friday, 14'th Nov 2025
Merck & Co. has struck a $9.2 billion deal to buy biotechnology company Cidara Therapeutics in a move that bolsters the drugmaker's respiratory portfolio.
Merck bets on flu prevention with about $9.2 billion deal for Cidara Therapeutics
06:51am, Friday, 14'th Nov 2025
Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, the companies said on Friday, gaining access to an experimental drug for flu prevention.
Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent
06:45am, Friday, 14'th Nov 2025
RAHWAY, N.J. & SAN DIEGO, Calif.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”), a biotechnology
Wall Street Breakfast Podcast: Merck Talks Send Cidara Soaring
06:09am, Friday, 14'th Nov 2025
Merck (MRK) is close to acquiring Cidara Therapeutics (CDTX) in a deal potentially exceeding $3.3 billion, with announcement expected soon. CDTX shares surged 85% on news of the potential acquisition,
Merck to acquire Cidara Therapeutics for $9.2B
04:29am, Friday, 14'th Nov 2025
Merck & Co Inc (NYSE:MRK, ETR:6MK) announced it has agreed to acquire Cidara Therapeutics Inc (NASDAQ:CDTX) in a $9.2 billion cash deal, paying $221.50 per...
Merck nearing deal for Cidara, FT reports
06:53pm, Thursday, 13'th Nov 2025
Merck is closing in on a deal to buy Cidara Therapeutics in a deal valuing the biotechnology company at a premium to its $3.3 billion market capitalization, the Financial Times reported on Thursday.
Cidara Therapeutics, Inc. (CDTX) Q3 2025 Earnings Call Transcript
02:56pm, Friday, 07'th Nov 2025
Cidara Therapeutics, Inc. ( CDTX ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Jeffrey Stein - President, CEO & Executive Director Nicole Davarpanah - Chief Medical Officer
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
04:07pm, Thursday, 06'th Nov 2025
Announced expanded and accelerated Phase 3 Plan for CD388, its non-vaccine influenza preventative therapeutic Enrolled and dosed first patients in Phase 3 ANCHOR study; target enrollment on track for
Cidara Therapeutics to Participate in November Investor Conferences
08:00am, Tuesday, 28'th Oct 2025
SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeuti
Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025
04:05pm, Thursday, 23'rd Oct 2025
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunother
Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025
08:00am, Thursday, 23'rd Oct 2025
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeuti
